RxDoctor Payments Data

Kristin Mahan, MD

Family Medicine · Vincennes, INNPI 1487622957

Payments from drug & device makers

$5,046in general payments, 2019–2025

Across 369 payments — averaging $13.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$804
  • Novo Nordisk$689
  • Amgen$529
  • Lilly USA, LLC$326
  • Pfizer$307
  • AstraZeneca$243
  • plus $2K from 45 others

What the payments were for

  • Food & beverage$5,046100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,046 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$10,370
Medicare patients
70
Services billed
127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin45$60,347
OzempicSemaglutide36$38,636
MounjaroTirzepatide32$36,844
EliquisApixaban20$31,352
XareltoRivaroxaban21$25,002
Repatha SureclickEvolocumab20$20,619
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$11,248
Tresiba Flextouch U-100Insulin Degludec18$10,088
Dexlansoprazole DrDexlansoprazole19$6,738
Tresiba Flextouch U-200Insulin Degludec11$6,466
Breo ElliptaFluticasone/Vilanterol12$5,344
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$4,836
Nebivolol Hcl19$2,498
Atorvastatin Calcium338$2,200
Ezetimibe82$2,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$75$60,34745 claims
Novo NordiskOzempic$689$38,63636 claims
Lilly USA, LLCMounjaro$326$36,84432 claims
PfizerEliquis$307$31,35220 claims
Johnson & JohnsonXarelto$40$25,00221 claims
GSKBreo Ellipta, Anoro Ellipta$201$10,18024 claims
AbbVieSynthroid$804$1,30417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Vincennes

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →